BioCentury
ARTICLE | Company News

Celgene gets options to Dragonfly's NK receptor antibodies

June 12, 2017 7:45 PM UTC

Dragonfly Therapeutics Inc. (Cambridge, Mass.) and Celgene Corp. (NASDAQ:CELG) began a five-year collaboration to discover, develop and commercialize candidates to treat hematologic malignancies based on Dragonfly’s TriNKET (Trispecific NK cell Engager Therapies) platform.

Celgene will have an exclusive option to obtain exclusive, worldwide rights for up to four candidates. Dragonfly will receive $33 million up front and is eligible for milestones and royalties. Dragonfly did not respond to inquiries...